{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:32Z","timestamp":1794002132390,"version":"4.8.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>B7-H3-targeted antibody-drug conjugates (B7-H3-targeted ADCs) have shown promising antitumor effects in patients with previously treated small cell lung cancer (SCLC), yet the available evidence on their efficacy and safety has not been systematically synthesized. This study aimed to systematically evaluate the efficacy and safety of B7-H3-targeted ADCs and contextualize their clinical outcomes against standard-dose intravenous topotecan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. PubMed, Embase, and the Cochrane Library were searched from inception to July 7, 2026. Prospective single-arm studies of B7-H3-targeted ADCs and randomized controlled trials (RCTs) with separately extractable topotecan arms were included. Study quality was assessed using the Newcastle\u2013Ottawa Scale and Cochrane RoB 2 tool. Random-effects models were used to pool efficacy and safety outcomes. Evidence from the two treatment groups was synthesized separately. Results for B7-H3-targeted ADCs were descriptive, whereas topotecan was used solely as an external clinical benchmark; therefore, the contextual comparison should not be interpreted as a direct comparative estimate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies were included, comprising four prospective single-arm studies of B7-H3-targeted ADCs and six RCTs with eligible topotecan arms. For B7-H3-targeted ADCs, the pooled objective response rate (ORR) and disease control rate (DCR) were 54% (95% CI: 46%\u201362%) and 89% (95% CI: 85%\u201392%), respectively. The pooled median duration of response and median progression-free survival were both 5.6 months (95% CI: 4.8\u20136.4 and 4.7\u20136.5 months, respectively). The pooled incidences of any-grade and grade \u22653 treatment-related adverse events were 99% (95% CI: 98%\u2013100%) and 61% (95% CI: 55%\u201367%), respectively. In the exploratory contextual analysis, ifinatamab deruxtecan achieved an ORR of 49% (95% CI: 41%\u201357%) and a DCR of 87% (95% CI: 81%\u201392%), whereas the corresponding estimates for topotecan were 18% (95% CI: 15%\u201322%) and 65% (95% CI: 61%\u201369%). Overall, the exploratory comparison showed numerically higher efficacy estimates and selected safety differences favoring ifinatamab deruxtecan compared with topotecan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B7-H3-targeted ADCs show promising clinical activity in patients with previously treated SCLC. In the exploratory contextual comparison, ifinatamab deruxtecan showed numerically favorable efficacy estimates and selected safety outcomes compared with topotecan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD420251237597, version 3.0.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1907324","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:37Z","timestamp":1786599157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiahui","family":"Wang","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzi","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Liu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Liu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyan","family":"Yin","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, The First People\u2019s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Yi","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","article-title":"The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf332","article-title":"Antibody drugs conjugates in small-cell lung cancer: present-day status and promises","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1516419","article-title":"Antibody-drug conjugates in cancer therapy: applications and future advances","volume":"16","author":"Long","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0019","article-title":"Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody-drug conjugates","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108723","article-title":"Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer","volume":"207","author":"Kurosaki","year":"2025","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12672-024-01171-1","article-title":"Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research","volume":"15","author":"Meng","year":"2024","journal-title":"Discov Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7:CD28 family and friends: unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7-H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3981","article-title":"Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes","volume":"31","author":"Gay","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","article-title":"mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0374","article-title":"EBV-upregulated B7-H3 inhibits NK cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression","volume":"11","author":"Chen","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-1538","article-title":"Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115710","article-title":"The recent developments of camptothecin and its derivatives as potential anti-tumor agents","volume":"260","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S12160484","article-title":"Topotecan: an evolving option in the treatment of relapsed small cell lung cancer","volume":"3","author":"Garst","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02110","article-title":"RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PloS Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","article-title":"HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: results from the ARTEMIS-001 phase 1a\/b trial","volume":"44","author":"Duan","year":"2026","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s1470-2045(25)00733-8","article-title":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial","volume":"27","author":"Johnson","year":"2026","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000588","article-title":"Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy","volume":"10","author":"Evans","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01055-5","article-title":"A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer","volume":"124","author":"Kang","year":"2021","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225368","article-title":"Unlocking new horizons in small-cell lung cancer treatment: the onset of antibody-drug conjugates","volume":"15","author":"Belluomini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306309","article-title":"Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1446","article-title":"Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy","volume":"19","author":"Torasawa","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2512566","article-title":"Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer","volume":"34","author":"Wespiser","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1408051","article-title":"Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature","volume":"14","author":"Wu","year":"2024","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111926","article-title":"Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration","volume":"132","author":"Li","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003099","article-title":"B7-H3 in acute myeloid leukemia: from prognostic biomarker to immunotherapeutic target","volume":"137","author":"Tan","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14182023","article-title":"B7H3 immune checkpoint overexpression is associated with decreased complete response rates to neoadjuvant therapy in locally advanced rectal cancer","volume":"14","author":"Curcean","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000001214","article-title":"Antibody-drug conjugates: new drugs - new toxicities","volume":"38","author":"Wong","year":"2026","journal-title":"Curr Opin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.32604\/or.2026.078000","article-title":"Engineering the future of ADCs in non-small cell lung cancer","volume":"34","author":"Kim","year":"2026","journal-title":"Oncol Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41698-025-01011-7","article-title":"Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment","volume":"9","author":"Marchesi","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/jipo-23-18","article-title":"B7-H3 inhibitors in oncology clinical trials: a review","volume":"7","author":"Feustel","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2025","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps8126","article-title":"IDeate-Lung02: a phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician's choice (TPC) in relapsed small cell lung cancer (SCLC)","volume":"42","author":"Owonikoko","year":"2024","journal-title":"J Clin Oncol"},{"key":"B61","unstructured":"ARTEMIS-008:HS-20093 compared with topotecan in subjects with relapsed small cell lung cancer\n          \n          \n          \n          2024"},{"key":"B62","unstructured":"A phase III study of YL201 in relapsed small cell lung cancer\n          \n          \n          \n          2024"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:39Z","timestamp":1786599159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2026.1907324"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1907324","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1907324"}}